Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipo-MERIT vaccine in advanced melanoma
NCT02410733Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Mar 2015
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enomimeran in melanoma, sponsored by BioNTech SE. Primary endpoint: Number of Adverse Events as a Measure of safety and tolerability at 8 years. Started Mar 2015; status: completed.
02
Drugs
enomimeran
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02410733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410733.